Craft

Nektar Therapeutics

Stock Price

$1.3

2024-10-29

Market Capitalization

$233.8 M

2024-10-29

Revenue

$90.1 M

FY, 2023

Nektar Therapeutics Summary

Company Summary

Overview
Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.
Type
Public
Status
Active
Founded
1990
HQ
San Francisco, CA, US | view all locations
Website
http://www.nektar.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jeff Ajer, Director

    • Robert B. Chess, Chairman of the Board

      • Gil M. Labrucherie, Chief Operating Officer and Chief Financial Officer

        • R. Scott Greer, Director

          LocationsView all

          3 locations detected

          • San Francisco, CA HQ

            United States

            455 Mission Bay Boulevard South, San Francisco

          • Huntsville, AL

            United States

            1112 Church St NW

          • Hyderabad, TG

            India

            Main Rd, Hashmath Gunj, Goutam Nagar, Badi Chowdi, Kachiguda

          Nektar Therapeutics Financials

          Summary Financials

          Revenue (Q3, 2024)
          $24.1M
          Gross profit (Q3, 2024)
          $19.7M
          Net income (Q3, 2024)
          ($37.1M)
          Cash (Q3, 2024)
          $30.1M
          EBIT (Q3, 2024)
          ($34.3M)
          Enterprise value
          $311.9M

          Footer menu